---
layout: post
title: 欧盟调查减肥药诺和泰是否会增加自杀倾向
date: 2023-07-11 09:33:05.000000000 +08:00
link: https://cn.wsj.com/amp/articles/%E6%AC%A7%E7%9B%9F%E8%B0%83%E6%9F%A5%E5%87%8F%E8%82%A5%E8%8D%AF%E8%AF%BA%E5%92%8C%E6%B3%B0%E6%98%AF%E5%90%A6%E4%BC%9A%E5%A2%9E%E5%8A%A0%E8%87%AA%E6%9D%80%E5%80%BE%E5%90%91-1f73303b
categories: wsj
---

<main id="main" role="main">
<div>


</div>
<div itemprop="articleLead" data-sbId="CN-BIZ-20230711074016">
    <div>
      <div class="media-object scope-
          header
">
          <figure>
      <div>
        <img
          srcset="https://images.wsj.net/im-814195?width=540&amp;size=1.5005861664712778 540w, https://images.wsj.net/im-814195?width=620&amp;size=1.5005861664712778 620w, https://images.wsj.net/im-814195?width=639&amp;size=1.5005861664712778 639w, https://images.wsj.net/im-814195?width=860&amp;size=1.5005861664712778 860w, https://images.wsj.net/im-814195?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=1.5 1290w, https://images.wsj.net/im-814195?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=2 1720w, https://images.wsj.net/im-814195?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=3 2580w"
          src="https://images.wsj.net/im-814195?width=860&amp;height=573"
          layout="responsive"
          placeholder
          alt="">
        </img>
      </div>
      <figcaption>
        <p>一支总部位于丹麦的诺和诺德生产的诺和泰。</p>
    <p> 图片来源：F. Martin Ramin/The Wall Street Journal</p>
  </figcaption>
</figure>

      </div>
    </div>
</div>
<div data-sbId="CN-BIZ-20230711074016">

<div>

  <div>
      <p> </p>
              <p><span itemprop="name">
                <a href="https://www.wsj.com/news/author/melanie-evans" itemprop="url" rel="author">Melanie Evans</a>
              </span></p>

  </div>
    <time>
      2023年7月11日08:30 CST 更新
    </time>
</div>

<div subscriptions-actions subscriptions-display="NOT data.noSharing">
  <div>
    <social-share type="system" width="72" height="24"
      data-param-url="https://cn.wsj.com/articles/欧盟调查减肥药诺和泰是否会增加自杀倾向-1f73303b">
    </social-share>
  </div>
</div>


<div subscriptions-section="content">
</div>
<div subscriptions-section="content-not-granted">
</div>



<section subscriptions-section="content">
      <p>欧洲药品安全监管部门正在对诺和泰(Ozempic)进行审查，此前收到了与这种流行的减肥药和另一种同类药物有关的自杀念头的报告。</p>
      <p>欧洲药品管理局(EMA)周一表示，在得知三名服药者报告有自残或自杀念头后，该局正在评估患者服用诺和诺德(Novo Nordisk, NVO)生产的这类药物的安全风险。</p>
      <p>EMA称，在欧盟，自杀行为未被列为诺和泰和一种名为Saxenda的相关药物的副作用。</p>
      <p>诺和诺德称，该公司对诺和泰和Saxenda的研究以及对其使用的持续监测未显示出该药与自杀想法或自残念头有关。</p>
      <div> <p>总部位于丹麦的诺和诺德在纽约证券交易所挂牌的美国存托股票周一午盘持平。</p>
      <p><strong>相关阅读：</strong></p>
      <p><a href="https://cn.wsj.com/articles/CN-BIZ-20230414083047" target="_blank" >“金刚级”减肥药将至</a></p>
      </div>
</section>

</div>
      </main>
